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Cyclopeptides containing the DEKS motif as
conformationally restricted collagen telopeptide
analogues: synthesis and conformational analysis†
Robert Wodtke,a,d Gloria Ruiz-Gómez,b Manuela Kuchar,a,d M. Teresa Pisabarro,b
Pavlina Novotná,c Marie Urbanová,c Jörg Steinbach,a,d Jens Pietzscha,d and
Reik Löser*a,d
The collagen telopeptides play an important role for lysyl oxidase-mediated crosslinking, a process which
is deregulated during tumour progression. The DEKS motif which is located within the N-terminal telo-
peptide of the α1 chain of type I collagen has been suggested to adopt a βI-turn conformation upon
docking to its triple-helical receptor domain, which seems to be critical for lysyl oxidase-catalysed deami-
nation and subsequent crosslinking by Schiﬀ-base formation. Herein, the design and synthesis of cyclic
peptides which constrain the DEKS sequence in a β-turn conformation will be described. Lysine-side
chain attachment to 2-chlorotrityl chloride-modiﬁed polystyrene resin followed by microwave-assisted
solid-phase peptide synthesis and on-resin cyclisation allowed for an eﬃcient access to head-to-tail
cyclised DEKS-derived cyclic penta- and hexapeptides. An Nε-(4-ﬂuorobenzoyl)lysine residue was
included in the cyclopeptides to allow their potential radiolabelling with ﬂuorine-18 for PET imaging of
lysyl oxidase. Conformational analysis by 1H NMR and chiroptical (electronic and vibrational CD) spec-
troscopy together with MD simulations demonstrated that the concomitant incorporation of a D-proline
and an additional lysine for potential radiolabel attachment accounts for a reliable induction of the
desired βI-turn structure in the DEKS motif in both DMSO and water as solvents. The stabilised confor-
mation of the cyclohexapeptide is further reﬂected by its resistance to trypsin-mediated degradation. In
addition, the deaminated analogue containing allysine in place of lysine has been synthesised via the
corresponding ε-hydroxynorleucine containing cyclohexapeptide. Both ε-hydroxynorleucine and allysine
containing cyclic hexapeptides have been subjected to conformational analysis in the same manner as
the lysine-based parent structure. Thus, both a conformationally restricted lysyl oxidase substrate and
product have been synthetically accessed, which will enable their potential use for molecular imaging of
these important enzymes.
Introduction
Enzymes that act on peptides and proteins very often recognise
their substrates in certain favoured conformations. This is
especially well understood for proteases,1 while for other
enzymes that participate in modifications of amino acid side
chains the situation is less clear. Lysyl oxidase, an enzyme
which catalyses the oxidative deamination of protein-bound
lysine residues to the corresponding aldehydes called allysines
(Scheme 1), is involved in the crosslinking of extracellular
matrix proteins such as collagen and elastin.2,3 Lysyl oxidases
Scheme 1 Lysyl oxidase-catalysed oxidative deamination of protein-
bound lysine residues to allysine.
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have been identified as key players in the processes of hypoxia-
induced tumour invasion and metastasis by remodelling the
extracellular matrix mainly through crosslinking of type I
collagen.6–8 Therefore, these enzymes represent a highly attrac-
tive target for functional molecular imaging of tumours.
Among the diﬀerent imaging modalities, positron emission
tomography (PET) is unparalleled in terms of sensitivity
and quantification and requires the development of target-
tailored molecular probes labelled with positron-emitting
radionuclides.9
For type I collagen, one major crosslink pathway involves
the condensation of an allysine carbonyl with the amino group
of an unmodified lysine or hydroxylysine residue to a Schiﬀ
base-type linkage.10 Notably, this process seems to occur spon-
taneously without enzymatic assistance. Especially well under-
stood is the crosslinking process where the lysine residue
located in the N-terminal telopeptide of the α1(I) chain under-
goes oxidation to act as aldehyde donor towards a (hydroxy)-
lysine (930) residue located at the α1 chain in the C-terminal
region of the triple-helical portion of another type I collagen
molecule.5,11 On the basis of the Chou–Fasman algorithm and
molecular modelling studies, it has been proposed that the
N-terminal α1(I) telopeptide adopts a hairpin-like conformation
with the central sequence Asp-Glu-Lys-Ser (DEKS) forming a
β-turn.11 This model has been supported experimentally on
the basis of 1H NMR and ECD12,13 as well as IR14 spectroscopic
analysis. In detail, these investigations revealed a confor-
mation for the DEKS motif that is in agreement with a type I
β-turn. Extended molecular modelling studies made evident
that the triple-helical region around lysine 930 constitutes a
recognition site that is complementary to the hairpin-like
shaped N-telopeptide of the α1 chain (Fig. 1).5 Detailed investi-
gations to unravel the structural determinants contributing to
the substrate properties of telopeptides concerning their con-
version by lysyl oxidase have been performed by Nagan and
Kagan. This study indicated the requirement of the interaction
with the triple-helical region around Lys 930, as the negative
charge of the Glu preceding the lysine residue at the telopep-
tide undergoing oxidation has to be compensated for eﬃcient
enzymatic conversion. Furthermore, the conformation of the
peptide chain containing the Lys residue to be deaminated
seems to be of importance for its recognition by the enzyme
itself, as a telopeptide derivative containing Pro N-terminal
before Lys exhibited the most favourable kinetic parameters.15
To image lysyl oxidase in vivo, the design of radiolabelled
probes based on the α1(I)-N-telopeptide seems to be promising
as their conversion will lead to aldehydes that can react with
amino groups on collagen strands which may result in a signal
enrichment on sites of enzymatic activity. As this will require
the interaction of the probe molecule with collagen we envi-
saged stabilising a potential lysyl oxidase substrate derived
from the α1(I)-N-telopeptide in a β-turn-like conformation.
The most promising approach to stabilise the DEKS
sequence in the crucial turn seems to be its incorporation in
head-to-tail cyclised peptides. This approach should be most
feasible for cyclic penta- and hexapeptides, as their con-
formational properties are well understood.16–20 Nevertheless,
the use of these macrocycles in biomedical applications is
rather scarce as their synthesis can be challenging and
cumbersome.21–24 Besides potentially enhanced target inter-
action, the cyclisation of peptides very often leads to improved
pharmacokinetic properties over their linear counterparts,20,25
Fig. 1 Model of the α1(I)-N-telopeptide docked to the triple-helical receptor region of bovine type I collagen. Left and Middle: The α1(I) chains are
shown in green, the α2(I) chain in yellow and the α1(I)-N-telopeptide in purple each in ribbon plots. For the zoomed area, the βI-turn forming DEKS
sequence in the α1(I)-N-telopeptide and the Lys930 in the collagen triple helix are represented in the stick model, the proposed hydrogen bond
between Asp10N and Ser7N is depicted by the dotted line. Right: the α1(I) and α2(I) chains are shown in the surface model (grey = carbon, red =
oxygen, blue = nitrogen) and the α1(I)-N-telopeptide is shown in stick representation (purple = carbon, red = oxygen, blue = nitrogen). All ﬁgures
were prepared with PyMOL4 using the model developed by Malone et al.5 based on the ﬁle “Malone_etalFig1d3ce.pdb” included in the Supporting
Information of that article.
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which was a further motivation of this work. In order to allow
the attachment of the radiolabel, an additional amino acid
had to be introduced. For the development of PET tracers
based on small molecules, the positron emitter fluorine-18
represents the most advantageous radionuclide.26,27 Therefore,
a 4-fluorobenzoyl group has been chosen to be attached to the
side chain of a second lysine residue to allow the perspective
labelling with fluorine-18 of the designed cyclopeptides.28
Herein we report on the synthesis of cyclic peptides contain-
ing the telopeptide-derived DEKS motif together with its ally-
sine-containing analogue and their conformational analysis in
both DMSO and water on the basis of NMR and chiroptical spec-
troscopy supported by molecular dynamics (MD) simulations.
To assess the intrinsic turn-forming propensities of the DEKS
motif, a linear analogue was synthesised and its enzymatic stabi-
lity was investigated in comparison to the cyclohexapeptides.
Results and discussion
Synthesis
Initially, the conformational restriction of the DEKS motif was
attempted within the cyclic pentapeptide 2 (Scheme 2). To this
end, Fmoc-Lys-OAll (1) was prepared according to a published
procedure29 and attached to the 2-chlorotrityl chloride resin (2-
ClTrtCl resin) resulting in a loading degree of 0.26 mmol g−1.
The corresponding resin-bound Fmoc-protected pentapeptide
ester was sequentially deprotected at its C- and N-termini. This
procedure ensures that the macrocycle-forming amide bond
coupling will occur at a hydrogen-bonded peptide bond of the
intended β-turn.30 Conditions for allyl ester cleavage were
selected according to Horne et al. using Pd(PPh3)4 as catalyst
and a solution of N-methylmorpholine and acetic acid in
dichloromethane as allyl scavenger.31 To obtain the desired
cyclopentapeptide, the resin-bound terminally deprotected
pentapeptide was treated with HATU and DIPEA. Minicleavage
followed by ESI-MS analysis indicated that the cyclisation pro-
cedure had to be repeated twice until no linear precursor was
detectable. The amino group of the Dde-protected lysine was
released by repetitive treatment with 2% hydrazine/DMF moni-
tored spectrophotometrically followed by 4-fluorobenzoylation
using 4-fluorobenzoyl chloride and triethylamine in dichloro-
methane. Cleavage from the resin and concomitant side chain
deprotection yielded the desired DEKS and 4-fluorobenzoyl
lysine containing cyclopentapeptide 2. HPLC analysis of the
crude product indicated the presence of substantial amounts
Scheme 2 Synthesis of cyclo(Ser-Lys(FBz)-Asp-Glu-Lys) (2) and cyclo(Ser-D-Pro-Lys(FBz)-Asp-Glu-Xaa) (3, 8, 9). Reagents and conditions: (a)
1. Fmoc-Lys-OAll × TFA, DIPEA, THF, 2 h, 2. CH2Cl2–CH3OH–DIPEA (17/1/2), 3 × 2 min; (b) Fmoc-Hnl-OAll, pyridine, CH2Cl2–DMF (1/1), 24 h or 65 h,
2. CH2Cl2–CH3OH–DIPEA (17/1/2), 3 × 2 min; (c) SPPS; (d) Pd(PPh3)4, CH2Cl2–NMM–CH3COOH (8 : 2 : 1), Ar, 4 h; (e) 20% piperidine/DMF, 2 × 8 min;
(f ) HATU, DIPEA, DMF, 1–3 × 4 h; (g) 2% N2H4–DMF, 5–12 × 5 min; (h) 4-ﬂuorobenzoyl chloride, TEA, CH2Cl2, 2 h; (i) TFA–TES–H2O (95 : 2.5/2.5),
3 h; ( j) TFA–TES–CH2Cl2 (1/5/94), 30 min; (k) Dess-Martin periodinane, CH2Cl2, 3 h; (l) TFA–CH2Cl2 (9/1), 1 h.
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of side products that eluted at significantly greater retention
times represented by a broad peak. These major impurities
were assigned as oligomerisation/polymerisation products
resulting from processes competing with cyclisation. The
occurrence of these side products, despite the low initial
loading of 0.26 mmol g−1, may reflect the poor tendency for
cyclisation of the linear pentapeptide precursor. Isolation of
the product from the crude mixture furnished the 4-fluoroben-
zoylated cyclopentapeptide 2 in 22% yield. 1H NMR analysis of
2 in DMSO at varying temperatures revealed chemical shift-
temperature gradients for the amide protons <−2.5 ppb K−1,
which indicates the absence of a defined secondary structure
in this cyclic peptide (data not shown).
The synthesis of 2 resulted in low yields and no evidence
for a stabilised structure was discernible. For this reason, it
was envisaged to include a further amino acid acting as turn-
inducing element. As both D-amino acids and proline are to be
found frequently in position i + 1 of β-turns, the incorporation
of one of these amino acids into the peptide chain can strongly
support or induce turn formation.32,33 D-Proline combines
both structural features and has therefore the potential to
induce turn-like conformations in cyclic hexapeptides as
demonstrated by Matter and Kessler.34 Thus, it was decided to
insert a D-proline between the N-terminal serine and the lysine
to be fluorobenzoylated (Scheme 2). Assuming the added
residue will adopt the i + 1 position of a β-turn, Ser, Lys(FBz),
and Asp would be found in the positions i, i + 2, and i + 3,
respectively. Potentially, this arrangement could lead to hydro-
gen bonding between the carbonyl oxygen of Ser and the
amide NH of Asp, which would preorganise these residues for
the formation of a second β-turn where they adopt the posi-
tions of i + 3 and i, respectively. Cyclisation of the linear hexa-
peptidic precursor was done as in the synthesis of 2. Notably,
no repetition of the cyclisation procedure was necessary, which
might reflect its stronger turn-forming propensity compared to
the linear pentapeptide precursor. According to HPLC analysis,
the content of 3 in the crude product was 80%, whereas that of
2 was only 22%.
As the oxidation reaction catalysed by lysyl oxidase leads to
the transformation of a primary amine to its corresponding
aldehyde, the synthesis of the allysine derivative 9 of cyclo-
hexapeptide 3 via its hydroxy analogue 8 was envisaged
(Scheme 2). To conserve the preparative strategy, Fmoc-Hnl-
OAll (7) (Hnl: ε-hydroxynorleucine) was intended to be
attached to the 2-ClTrtCl resin. Subsequent construction of the
hexapeptide, cyclisation, and cleavage under conservation of
the tBu side chain protection groups should be followed by oxi-
dation of the primary alcohol to the allysine-containing cyclo-
hexapeptide and final deprotection. The synthesis of amino
acid 7 was achieved in four steps (Scheme 3). Nα-Boc-protected
L-ε-hydroxynorleucine (4) was accessible in satisfying yields by
a chiral pool synthesis based on the diazotation of Nα-Boc-
lysine with sodium nitroprusside and hydrolysis of the inter-
mediate diazonium salt in a one-pot sequence published by
Glenn et al.35 Treatment of 4 with allyl bromide furnished the
Boc-protected L-ε-hydroxynorleucine allyl ester (5). Surprisingly,
removal of the Boc group of 5 by treatment with trifluoroacetic
acid was accompanied by trifluoroacetylation at the ε-hydroxyl
group. As compound 6 was Fmoc-protected at its α-amino
group under slightly basic aqueous conditions, the trifluoro-
acetic acid ester was quantitatively hydrolysed to the corres-
ponding alcohol 7, which was the required building block for
resin attachment.
Loading of 7 to the 2-ClTrtCl resin was tried under the
same conditions as for the amino analogue Fmoc-Lys-OAll (1),
but it resulted in no detectable resin attachment due to the
low nucleophilicity of the hydroxyl group. Applying conditions
developed for the functionalisation of the 2-ClTrtCl resin with
Fmoc-protected amino alcohols, which employ pyridine in
excess as base and prolonged reaction times,36 led to a loading
degree of 0.86 mmol g−1 when one equivalent of 7 and a reac-
tion time of 65 h was used. Construction of the hexapeptide
sequence, cyclisation, and fluorobenzoylation was done
according to the synthesis of the amino analogue. The
increased resin loading of 0.86 mmol g−1 compared to
0.26 mmol g−1 in the synthesis of the lysine-containing cyclo-
hexapeptide 3 did not have detrimental eﬀects on the cyclisa-
tion, as confirmed by ESI-MS analysis of the product obtained
by minicleavage of the Dde-protected cyclohexapeptide. Analy-
sis of the fluorobenzoylated L-ε-hydroxynorleucine-containing
cyclo-hexapeptide 8 released from the resin indicated the pres-
ence of an undesired component exhibiting a molecular mass
that is 96 units higher than the product, which has been
assigned to result from trifluoroacetylation at a free hydroxyl
group. This esterification must occur at the hydroxyl group of
L-ε-hydroxynorleucine rather than that of serine, as trifluoro-
acetylation has not been observed for cyclohexapeptide 3. Gen-
erally, trifluoroacetylation in solid-phase peptide synthesis
during TFA-mediated cleavage has been reported only for
N-terminal serine and threonine residues but not for internal
ones.37 As trifluoroacetylation was also encountered along the
route to building block 7 during TFA-mediated Boc deprotection
Scheme 3 Synthesis of Fmoc-Hnl-OAll (7). Reagents and conditions:
(a) sodium nitroprusside, 4 M NaOH, pH = 9–10, 6 h at 60 °C; (b) allyl
bromide, DIPEA, DMF, 16 h at rt; (c) CH2Cl2–TFA (1 : 1, v/v), 2 h at rt; (d)
Fmoc-OSu, 0.62 M Na2CO3, DME, 2 h at 4 °C to rt.
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of 5, it can be concluded that the nucleophilicity of the
hydroxyl group of the L-ε-hydroxynorleucine must be increased
due to sterical and/or electronical reasons. To hydrolyse the
TFA ester, the crude material was dissolved in a 1 : 1 mixture of
acetonitrile and water and kept at room temperature overnight.
ESI-MS analysis clearly confirmed the complete hydrolysis of
the TFA ester under these conditions. Purification by prepara-
tive HPLC revealed the existence of side products that eluted at
greater retention times than the product 8, which was already
observed for cyclopentapeptide 2 but not for cyclohexapeptide
3. Since the initial loading degree for the synthesis of 8
(0.86 mmol g−1) was significantly higher compared to 3
(0.23 mmol g−1), the generation of oligomerisation/polymeris-
ation products was probably favoured and competed against
the intramolecular cyclisation, even in the presence of
D-proline. After purification by preparative HPLC and lyophilisa-
tion of the product-containing fractions, the desired cyclohexa-
peptide 8 was obtained in 30% yield.
For the synthesis of the allysine-containing cyclohexapep-
tide 9, the loading procedure of Fmoc-Hnl-OAll (7) to the
2-ClTrtCl resin was repeated with a reduced amount of the
amino acid (1 eq. → 0.6 eq.) and shortened reaction time (65 h
→ 24 h). This variation resulted in a loading degree of
0.46 mmol g−1, which is still higher than that obtained with
Fmoc-Lys-OAll (1; 0.26 mmol g−1) but should be suﬃcient to
attenuate intermolecular reactions. To synthetically access the
allysine-containing cyclohexapeptide 9, the selective oxidation
of 8 was necessary. Oxidation of primary alcohols that stop at
the aldehyde level is reported to work very well by employing
the Dess-Martin periodinane as oxidising agent.38 As the
deprotected cyclohexapeptide 8 also contains another hydroxyl
group at its serine residue, this side chain should be protected
to prevent oxidation there. Release of peptides linked to
2-ClTrtCl resin via their C-terminal carboxy group without
aﬀecting the acid-labile side-chain protecting groups can be
conveniently accomplished by incubation with a 1 : 4 mixture
of hexafluoroisopropanol and dichloromethane.39 However,
when the resin containing fully protected 8 was subjected to
these conditions, the yield of the released peptide was very
low, as the 2-chlorotrityl ethers are obviously more acid-stable
than the corresponding esters. A good yield for cleavage of the
fully protected cyclohexapeptide (tri-tBu-8) was achieved with
TFA–TES–CH2Cl2 (1 : 5 : 94). Oxidation of tri-tBu-8 with Dess-
Martin periodinane and subsequent deprotection with TFA led
to the desired allysine-containing cyclohexapeptide 9. Analysis
by ESI-MS and 1H NMR clearly confirmed its identity as alde-
hyde. This is worth to note, as allysine-containing peptides
have been reported to be unstable due to dehydrative cyclisa-
tion to tetrahydropyridine derivatives.40,41 Even over several
months at room temperature in DMSO-d6, no changes were
discernible for the aldehyde group from the 1H NMR spec-
trum. This result is in agreement with a more recent study in
which no intrinsic instability of peptide-incorporated allysine
residues was observed either.42
To gain insight into the intrinsic conformational properties
of the DEKS motif, the linear version of cyclohexapeptide 3
formally resulting from a cut between the Lys(FBz) and D-Pro
moieties of the corresponding cyclic peptide, the central resi-
dues of the intended β-turn, was synthesised. To mask the
terminal charges, the required linear hexapeptide 10 (Fig. 2)
was N- and C-terminally acetylated and amidated, respectively,
and assembled by standard Fmoc solid-phase synthesis on
Rink amide resin. The 4-fluorobenzoyl residue was introduced
in analogy to the synthesis of the cyclic peptides.
Conformational analyses
The successful synthesis of the three cyclohexapeptides 3, 8
and 9 allowed the investigation of their solution confor-
mations by 1D and 2D 1H NMR experiments at 298 K in
DMSO-d6. On the basis of TOCSY experiments, it was possible
to assign all amide and CαH resonances in the
1H NMR
spectra of these cyclic peptides unambiguously. Notably, no
cis-amide bonds were detected. The larger dispersion in the
chemical shifts of the NH and CαH protons of the constrained
peptide 3 compared to the low chemical shift dispersion
observed on its linear version 10 indicates a more defined
structure for the cyclopeptide. This is particularly obvious for
the region of the CαH chemical shifts, which in the case of
cyclopeptide 3 shows distinctive signals for every proton
whereas the signals of the Asp and Ser as well as the Glu, Lys
and D-Pro Cα protons in the linear analogue 10 are overlapping
with each other, respectively. Values greater than 8 Hz for the
3JNHCHα coupling constants of the residues Lys(FBz), Asp, and
Lys, Aly or Hnl are consistent with a structure of restricted
flexibility.43 This assumption is supported by the presence of
medium to strong sequential dNN (i,i + 1) ROEs for the residues
Glu, Lys/Aly/Hnl and Lys(FBz) each in position i, which lose
the connectivity on the Asp residue. In addition, strong-
medium and weak dαN (i,i + 1) ROEs were detected for D-Pro
and Asp, and Lys/Aly/Hnl, Lys(FBz), Glu, respectively (Fig. 3).
Values for the chemical shift temperature coeﬃcients more
positive than −4 ppb K−1 were observed for the amide protons
of Asp, Glu, Lys/Hnl/Aly and Ser residues in all constrained
hexapeptides (Fig. 4). Generally, temperature coeﬃcients for
amide protons in DMSO more positive than −2 ppb K−1 are
considered indicative of intramolecular hydrogen bonds,
whereas values more negative than −4 ppb K−1 allow to con-
clude solvent-exposed NH-groups.17,44 The most positive tem-
perature coeﬃcients are exhibited by the amide protons of the
Asp and Ser residues, which indicates their involvement in
Fig. 2 Structure of the linear hexapeptide 10.
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intramolecular hydrogen bonds. This data combined with the
information obtained from the ROESY spectra allows to con-
clude the presence of a β-turn formed by the residues Ser,
D-Pro, Lys(FBz) and Asp stabilised by a i,i + 3 hydrogen bond
between Ser CO (i) and Asp NH (i + 3). Generally, the criterion
for the presence of a β-turn in a peptide sequence requires the
Cα atoms of the first (i) and fourth (i + 3) residues to be less
than 7 Å apart from each other.18,45,46 This feature implies for
a cyclic hexapeptide that the presence of one β-turn accounts
for the existence of a second β-turn for topological reasons.
Applied to the cyclohexapeptides 3, 8 and 9, this allows to
infer that also the telopeptide-derived DEXS (X = Lys, Hnl, Aly)
motif must form a β-turn-like structure, as Ser and Asp are
the terminal residues of both the tetrapeptide sequences
SpK(FBz)D and DEXS. This conclusion is in accordance with the
observed temperature coeﬃcient for the serine amide protons.
Taking into account the threshold value for temperature coeﬃ-
cients in DMSO outlined above, the value of −2.2 ppb K−1
observed for the amide proton of the unmodified lysine
residue is more ambiguous in regard to intramolecular
H-bonding, but it is unlikely that this amide proton is exposed
to the solvent. The chemical shift temperature coeﬃcients exhibi-
ted by the amide protons of the linear DEKS-containing hexa-
peptide 10 were all more negative than −4 ppb K−1 except for
the Glu NH (see MD section below), which allows to conclude
their solvent exposure and thus the absence of turn-like struc-
tures in this compound (Fig. 4).
Solution structures were calculated from a total of 37 (15
inter-residue), 34 (11 inter-residue), and 29 (11 inter-residue)
ROEs of 3, 8 and 9 in DMSO, respectively, four backbone ϕ-di-
hedral angle restraints derived from the amide coupling con-
stants (−120 ± 30° for 3JNHCHα > 8 Hz and −65 ± 30° for
3JNHCHα < 6 Hz), and two H-bond restraints i,i + 3 involving the
Asp and Ser residues (Fig. 3, S2 and Tables S1–S3 in ESI†).
Structures were calculated in XPLOR-NIH47 using a dynamic
simulated annealing (SA) protocol,48 followed by energy mini-
misation in the CHARMm force field.49 The 20 lowest-energy
structures of 3, 8 and 9 did not have any distance (≥0.2 Å) or
dihedral angle (≥2.4°) violations, converging with a backbone
RMSD of 0.25, 0.21, and 0.24 Å, respectively. The presence of
two β-turns flanked by Ser and Asp residues involving the
Fig. 3 Left: summary of amide NH temperature coeﬃcients (Δδ/T > −2 ppb K−1 shown by ●), 3JNHCHα coupling constants (>8 Hz represented by ↑
and <6 Hz shown by ↓) and ROEs correlations summary for cyclohexapeptide 3 in DMSO at 298 K. Right: 20-lowest energy structures of 3. For
clarity only the side chain of pro is shown. For summary and structures of cyclohexapeptides 8 and 9 see ESI (Fig. S2†). For distance restraints of
compounds 3, 8 and 9 see Tables S1–S3 in ESI.†
Fig. 4 Amide temperature coeﬃcients of the cyclohexapeptides 3, 3a,
8–9 and the linear hexapeptide 10 in DMSO or water (marked with *).
Temperature coeﬃcients more positive than −2.0 ppb K−1 (dashed red
line) or −4.5 ppb K−1 (dashed blue line) indicate that the amide proton is
part of an intramolecular hydrogen bond in DMSO and water, respect-
ively. For the values of the amide temperature coeﬃcients and plots of
the temperature dependence of chemical shifts for the amide protons
of 3, 3a, 8, 9 and 10 see ESI (Fig. S1†).
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sequences SpK(FBz)D and DEXS (X = Lys, Hnl, Aly) was conso-
lidated in all three constrained peptides. The Cα distances
between these flanking residues were 5.2 Å, which confirms
the compliance with the criterion for β-turns as noted
above.18,45,46 As expected, the turn involving D-Pro (i + 1) and
Lys(FBz) (i + 2) residues exhibited ϕ and ψ angle values consist-
ent with a type II reverse (II′) β-turn (Table 1). As previously
observed,50 the geometrical characteristics of this turn impose
short distances between the Cα atoms of the Ser and Asp flank-
ing residues in the cyclic structures, which allows to nucleate a
second β-turn around Glu (i + 1) and Xaa (Xaa = Lys, Hnl, Aly)
(i + 2) (Table 1). Their ϕ and ψ angles showed values which are
in accordance with a type I β-turn46 in 80–95% of the ensemble
structures.
DMSO is known to favour the formation of secondary struc-
tures in peptides.51 Given that the interaction of peptides with
other biomolecules in vivo occurs in aqueous solution, the con-
formational behaviour of 3 was also exemplarily studied in
water. NMR spectra of 3 at varying temperatures were acquired
in water, and the signals were assigned based on the 2D
TOCSY spectrum. As for 3 in DMSO, the dNN(i,i + 1) corre-
lations in the 2D ROESY spectrum in water between Asp-Lys
(FBz) and Lys-Ser clearly indicate the presence of the two
β-turns (Fig. S3 in ESI†). Due to spectra acquisition with
solvent suppression by water presaturation, it was not possible
to obtain quantitative ROE signals for the Cα protons. There-
fore, no solution structure could be calculated. Further evi-
dence for structural order in the peptidic backbone of 3 in
water is provided by considering the diﬀerences in the Cα
proton chemical shifts between the values observed and the
ones tabulated for random-coil conformations in water.52 As
Fig. 5 shows, the secondary chemical shifts of the “inner resi-
dues” in the proposed turn (Glu/Lys and D-Pro/Lys(FBz)) are
negative, whereas those of Asp and Ser, the residues bridging
both turns, are positive. To evaluate whether amide protons in
peptides and proteins participate in intramolecular hydrogen
bonds a temperature chemical shift coeﬃcient of −4.5 ppb K−1
is considered as threshold value in aqueous solution.53 Tem-
perature coeﬃcients more negative than this value indicate
solvent-exposed amide protons. Interestingly, all amide
protons of 3 in water display positive values, i.e. their chemical
shifts increase with temperature, which is equivalent to greater
deshielding of these protons at higher temperatures (Fig. 4).
This result suggests that the changes in the chemical shifts of
these protons over the observed temperature range is not
exclusively determined by their hydrogen bond behaviour, as
both intramolecular and intermolecular hydrogen bonds are
weakened with increasing temperature.
However, the NH protons of the residues that stabilise the
two β-turns by acting presumably as H bond donors, Asp and
Ser, exhibit the most positive values for Δδ/T. This finding is in
accordance with the results obtained for DMSO as solvent,
which indicates the similarity of the backbone conformations
of 3 in DMSO and water. Generally, the chemical shift tem-
perature coeﬃcients should be interpreted cautiously to gain
structural information, especially when the amide protons are
in the vicinity to an aromatic moiety, as their chemical shift
changes can be influenced by ring current eﬀects.53 To investi-
gate the influence of the 4-fluorobenzoyl moiety on the amide
chemical shift temperature coeﬃcients, the analogue of 3
lacking this group (compound 3a) was prepared. The NMR
analysis of 3a in water revealed that its amide protons are
slightly more deshielded than in 3 due to the lack of the aro-
matic ring current. Interestingly, the temperature coeﬃcients
for the chemical shifts of the amide protons in 3a did not
diﬀer significantly from those in 3, and the sequence of the
values was the same in both derivatives, which suggests that
the 4-fluorobenzoyl group has minor influence on the chemi-
cal shift temperature coeﬃcients of the amide protons (Fig. 4).
The presence of a stabilised secondary structure within
the cyclohexapeptides 3, 8 and 9 was further supported by
Table 1 Phi (ϕ) and Psi (ψ) dihedral angles (°) deﬁning two β-turns in cyclo(Ser-D-Pro-Lys(FBz)-Asp-Glu-Xaa) with Xaa = Lys (3), Hnl (8), Aly (9)
Compound ϕ(D-Pro) ψ(D-Pro) ϕ(Lys(FBz)) ψ(Lys(FBz))
3 63.6 ± 3.0 −108.0 ± 10.6 −91.5 ± 6.2a −5.9 ± 15.5
8 65.1 ± 2.3 −113.7 ± 8.1 −92.5 ± 6.9 −3.3 ± 13.7
9 64.9 ± 2.5 −110.4 ± 8.6 −90.4 ± 4.5 −10.7 ± 13.1
Compound ϕ(Glu) ψ(Glu) ϕ(Xaa) ψ(Xaa)
3 −57.4 ± 4.3 −12.4 ± 15.3 −90.5 ± 2.7b −23.2 ± 21.6
8 −58.1 ± 2.7 −19.7 ± 3.9 −89.9 ± 1.3c −26.7 ± 28.2
9 −53.5 ± 4.9 −20.1 ± 9.2 −88.7 ± 1.3d −18.4 ± 28.5
a 90% of the 20 ensemble structures, 10% ϕ = −131.6 ± 9.1. b 80% of the 20 ensemble structures, 20% ϕ = −150.2 ± 0.1. c 95% of the 20 ensemble
structures, 5% ϕ = −144.9. d 90% of the 20 ensemble structures, 10% ϕ = −139.9 ± 8.2.
Fig. 5 Secondary chemical shifts of Cα protons in cyclohexapeptide 3
in aqueous solution referenced to tabulated random coil values (Δδ =
δCHα(3) − δCHα(random coil)).52
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electronic circular dichroism (ECD) spectra recorded in
aqueous solution at diﬀerent concentrations and in the
absence and presence of 50% trifluoroethanol (TFE; Fig. 6).
The spectra of 3 and 8 show a strong negative maximum at
201 nm and a weaker positive maximum at 185 nm. This ECD
signature is in accordance with a type II reverse β-turn.54
Worth of note, no changes in the shape and intensity were
observed upon addition of trifluoroethanol. The spectra of the
allysine-containing analogue 9 are of similar shape even
though lower absolute values for the molar ellipticities are
exhibited. In contrast, the shape of the ECD spectrum of the
linear hexapeptide 10 is of distinct character and resembles
that of a type II poly(L-Pro) (PII) helix with a strong negative
maximum at 197 nm and a weak positive maximum at 231 nm
(Fig. 6).54 This motif of secondary structure has been very
often observed in short peptides.55 Similar as for 3, 8 and 9,
no major changes in the shape and intensity within the ECD
spectrum of 10 were observable upon addition of TFE.
Further evidence for the existence of a β-turn conformation
in 3, 8 and 9 can be derived from their IR absorption and
vibrational circular dichroism (VCD) spectra recorded in
DMSO (Fig. 7). Compared to ECD spectra, which reflect the
conformation of an oligopeptide as a whole, VCD spectra are
more sensitive to local diﬀerences in conformation as they are
derived from vibrational states and resemble an average con-
formation in the oligopeptide molecule.56 The absorption
bands in the IR spectrum of 3 are 1691, 1660, 1635, 1540, and
1504 cm−1. The corresponding VCD spectrum exhibits a
slightly positively biased negative couplet in the amide I
region with the positive component at 1689 cm−1 and the
negative component at 1658 cm−1. This signal is followed by a
negative couplet in the amide II region consisting of a positive
band at 1554 cm−1 and a negative band at 1523 cm−1. On the
basis of VCD investigations on small peptides with a β-hairpin
structure containing D-Pro in the position i + 1 of the central
β-turn,57 the absorption bands at 1691 cm−1 and 1635 cm−1
in the IR spectrum and the VCD band at 1689 cm−1 can be
attributed to the β-turn structure. The NMR-based structure
calculations clearly indicated a high propensity for compound
3 to adopt a turn-extended-turn structure. Therefore, the
absorption bands at 1660 cm−1 and the VCD band at
1658 cm−1 may result from the weak β-sheet character of this
kind of structure. In this context, it should be noted that the
IR and VCD bands of 3, which are attributed to the β-sheet
and βII′-turn proportions, respectively, are of approximately
equal intensities, in contrast to the β-hairpin structures investi-
gated by Zhao et al. where the β-sheet proportion is dominat-
ing.57 The VCD spectrum of the allysine-containing
cyclohexapeptide 9 is of similar signature in the amide
I-region as the one of 3. Obviously, the β-sheet-related IR and
VCD bands show stronger intensities in the case of the
ε-hydroxynorleucine analogue 8, which otherwise exhibits the
same band positions in the IR and VCD spectra as cyclohexa-
peptide 3. It is striking that the VCD spectrum of the linear
analogue 10 is of similar shape as those of 3, 8 and 9.
However, as deduced from the NMR results and the ECD
spectra, the structure of 10 must be distinct from that of the
cyclohexapeptides. The negatively biased negative amide I
couplet consisting of a positive component at 1683 cm−1 and a
negative component at 1660 cm−1 may indicate the presence
of a PII helix,
58 which is in agreement with the ECD results.
Fig. 6 ECD spectra of the cyclohexapeptides 3, 8, 9 and the linear ana-
logue 10 in aqueous solution in the absence and presence of triﬂuoro-
ethanol. The concentration of each peptide was 0.125 mg mL−1 The
spectra for 0.5 mg mL−1 can be found in Fig. S4 in ESI.†
Fig. 7 IR (top) and VCD (bottom) spectra of the cyclohexapeptides 3, 8,
9 and the linear analogue 10, and listing of characteristic signals in the
amide I region (max = maximum, pos = positive, neg = negative).
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The most significant hint for the absence of a β-turn-like struc-
ture in 10 is included in its IR spectrum, in which the band
around 1635 cm−1 is missing, while the cyclic counterparts
feature this vibrational transition (Fig. 7). Taken together, it
can be concluded that in this case ECD provides more infor-
mation regarding the secondary structure compared to VCD,
as the VCD spectra of the cyclopeptides and the linear hexa-
peptide 10 diﬀer only subtly from each other.
To gain further insight into the conformational behaviour
of the constrained peptides 3 and 9, MD simulations were per-
formed. Their conformational space was explored in DMSO
and water as solvents. One of the best NMR-calculated struc-
tures was selected in each case and simulated without
restraints for 100 ns using the ﬀ99SB force field59 and stan-
dard protocols as implemented in the AMBER12 package.60
The trajectories were analysed in terms of backbone RMSD,
backbone dihedral angles and H-bonding. The turn-extended-
turn conformations observed from NMR-calculations were also
dominant during the simulations in both DMSO and water
(Table 2, Fig. 8 and 9).
Comparison of the backbone dihedral angles involving
D-Pro, Lys(FBz), Glu, and Xaa (Xaa = Lys and Aly) in DMSO and
water showed consistency with the two β-turn types previously
identified (Table 2, ESI Fig. S5†). The type II reverse β-turn
with D-Pro at position i + 1 was well maintained during at least
96% of the simulation time in each solvent. The type I β-turn
involving Glu and Xaa (Xaa = Lys and Aly) residues was also
consistent for 82–87% of the sampled conformations. Hydro-
gen bond analysis shed further light about the conformational
space visited by the constrained cyclohexapeptides 3 and 9 in
the diﬀerent solvent environments (Fig. 9). The geometric cri-
terion used to calculate the presence of intramolecular hydro-
gen bonds in 3 and 9 involved distance and angle cutoﬀs of
3.5 Å and 120°, respectively. The hydrogen bond involving the
amide NH of Asp and the CO group of Ser showed similar
occupancy (88–92%) in both compounds. These data are in
good agreement with the experimentally determined amide
temperature coeﬃcients and provide evidence for the high
stabilisation of the type II reverse β-turn in these cyclic hexa-
peptides. In addition, the H-bond involving the amide NH of
Ser and the CO group of Asp was also observed, although with
lower occupancy (68% and 67% for 3 and 9 in DMSO, respect-
ively). The presence of this hydrogen bond dropped consider-
ably in water (38% and 39% for 3 and 9, respectively).
Consistent with the experimental data, the MD studies illus-
trate the presence of a highly populated H-bond in DMSO
(>90%) between the side chain of Asp and the amide NH of
Lys/Aly in 3 and 9, respectively (see Fig. S6 in ESI†). This result
is in accordance with previous studies on β-turns in peptides
Table 2 Phi (ϕ) and Psi (ψ) dihedral angles (°) obtained from MD simulations of 3 and 9 in DMSO and water
ϕ(D-Pro) ψ(D-Pro) ϕ(Lys(FBz)) ψ(Lys(FBz)) Turnc (%)
3a 66.3 ± 9.7 −122.1 ± 11.9 −83.3 ± 12.8 3.1 ± 17.2 97
3b 63.5 ± 10.0 −124.0 ± 13.4 −82.3 ± 14.1 0.1 ± 19.3 98
9a 66.1 ± 9.9 −119.9 ± 12.3 −84.4 ± 13.2 0.8 ± 16.3 96
9b 63.7 ± 9.8 −123.7 ± 13.5 −81.8 ± 13.8 −0.6 ± 19.2 98
ϕ(Glu) ψ(Glu) ϕ(Xaa) ψ(Xaa) Turnc (%)
3a −59.9 ± 10.4 −17.6 ± 11.4 −92.0 ± 14.0 −33.8 ± 12.3 82
3b −60.9 ± 11.5 −24.8 ± 16.8 −103.2 ± 22.0 −28.8 ± 18.8 87
9a −65.9 ± 9.1 −14.7 ± 10.6 −93.6 ± 15.2 −30.4 ± 13.5 86
9b −62.5 ± 11.3 −22.9 ± 15.4 −103.7 ± 22.3 −28.6 ± 19.0 86
aDMSO. bWater. c Calculated according to the angle deviations allowed around the ideal dihedral angles that define the classical type II reverse
β-turn and type I β-turn, respectively.46
Fig. 8 Backbone RMSD of 3 (black) and 9 (grey) in DMSO (top) and
water (bottom). Backbone RMSD referred to the mass-weighted least-
squares ﬁtting of the average structures after removal of overall transla-
tional and rotational motions of 100 ns MD simulations.
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and proteins, which pointed out that a hydrogen bond
between an acceptor atom in the functional side chain of the
residue at position i and the amide NH of residue at i + 2 is a
common feature of type I β-turns.34,61–63 Moreover, the posi-
tion i of type I β-turns in proteins is occupied by Asp in high
statistical probability.63,64 Upon changing the solvent from
DMSO to water the presence of the hydrogen bond between
the Asp side chain and the amide NH of Lys/Aly was reduced
by ca. 40%. To a similar extent (ca. 30%) dropped the occu-
pancy of the SerNH–AspCO H-bond, which indicates the con-
tribution of the i,i + 2 side chain-main chain interaction to the
stabilisation of the βI-turn. The loss of this H-bond was com-
pensated by an alternative contact between the Asp side chain
and the amide NH of Glu. As opposed to the results obtained
from NMR studies on the linear DEKS sequence, in which it
has been concluded that a salt-bridge between the side chains
of Glu and Lys could stabilise a type I β-turn (in CD3OH–H2O
(60/40) as solvent),13 low H-bond occupancy was observed
between these side chains in the constrained analogue 3 in
DMSO. In fact, the Asp and Lys residues showed a tendency to
form H-bond contacts between their side chains, which was
twice as high compared to the side chains of Glu and Lys. The
fact that the Glu-Lys side chain contact seems to be of negli-
gible importance for the stabilisation of the βI-turn is further-
more supported by the results of H-bond analysis from the MD
simulation for the allysine-derived cyclohexapeptide 9 (Fig. 9).
These indicate that the H-bond contacts between Asp(CO) and
Ser(NH), as well as between the Asp carboxylate and Aly(NH),
have similar propensities as in the lysine analogue 3. The
strong tendency for the formation of the Asp-Lys side chain
contacts in DMSO can be explained by the highly populated
H-bond between the Asp side chain and the amide NH of Lys,
which may preorganise the Asp residue for the formation of
that salt bridge while the side chain of Glu prefers to form
H-bond contacts with its amide NH (see ESI Fig. S6†).65 In con-
trast, the occupancy of both H-bonds is significantly decreased
in water. The intraresidual (backbone-side chain) H-bond in
the Glu residue has been also observed for the linear hexapep-
tide 10, as indicated by the low temperature coeﬃcient for the
amide NH of Glu in DMSO (Fig. 4).
The increased structural flexibility of the cyclohexapeptides
3 and 9 in aqueous solution compared to DMSO as solvent is
also reflected by the B factors for the backbone atoms of the
individual residues (see Fig. S7 in ESI†).
Enzymatic stability
To obtain information on the biological stability of cyclohexa-
peptide 3, its susceptibility against enzymatic cleavage was
investigated by HPLC in comparison to its linear counterpart
10. The presence of a lysine residue in these peptides renders
the peptide bond between this residue and the following
serine potentially prone towards proteolysis by the serine pro-
tease trypsin (EC 3.4.21.4). Compound 3 resisted degradation
in the presence of bovine trypsin over a time of 30 min, even
when stoichiometric amounts of the enzyme were employed
(Fig. 10).
In contrast, the linear analogue 10 was completely con-
verted within the same time already at a trypsin concentration
of 1 µM (see Fig. S8 in ESI†). These results provide further evi-
dence for a stabilised structure of 3, as most proteases are
unable to cleave peptide bonds within turn structures1 and,
furthermore, demonstrate the advantages of small cyclic pep-
tides with regard to metabolic stability.
Concluding remarks
The results of this study demonstrate that the collagen α1(I)-N-
telopeptide-derived DEKS motif can be successfully stabilised
in a type I β-turn as a part of a turn-extended-turn confor-
mation in cyclic hexapeptides and thus preorganised to inter-
act with its receptor region at type I collagen. D-Pro together
with Lys(FBz) were introduced strategically in the cyclohexa-
peptide to favour a type II′ β-turn and to nucleate a type I
β-turn in the DEKS collagen recognition sequence. Further-
more, the introduction of a second Lys residue allows the
attachment of a reporter group to enable the convenient func-
tionalisation with the radionuclide fluorine-18 for PET
imaging studies. This together with the evaluation of the sub-
strate properties towards lysyl oxidase-catalysed deamination is
subject of ongoing investigations. The replacement of the
DEKS-derived Lys residue by ε-hydroxynorleucine and allysine
did not compromise the structural stabilisation of the βI-turn
within this motif. The building block Fmoc-Hnl-OAll (7)
Fig. 9 H-bond analysis derived from the 100 ns trajectories in DMSO
(red) and water (blue). Top: cyclo(Ser-D-Pro-Lys(FBz)-Asp-Glu-Lys) (3),
Bottom: cyclo(Ser-D-Pro-Lys(FBz)-Asp-Glu-Aly) (9).
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required for the construction of these analogues was obtained
by an eﬃcient synthetic procedure which will account for the
synthesis of further Hnl/Aly-containing cyclopeptides.
Although the geometrical characteristics that define the type I
β-turn around DEKS sequence is maintained in both DMSO
and water, the occupancy of the H-bond involving the amide
NH Ser residue and the CO group of Asp decreased consider-
ably in the aqueous environment, which may have impli-
cations for the understanding of the collagen cross-linking
process. Spectroscopic investigations of the linear analogue 10
did not reveal an inherent turn-forming propensity for the
DEKS motif. Furthermore, the cyclic counterpart 3 was resist-
ant towards tryptic cleavage, as opposed to 10. These results
demonstrate the power of cyclic hexapeptides to constrain
tetrapeptide sequences in β-turn-like conformations with con-
comitantly achieving stability against proteolytic degradation.
Moreover, the combination of D-Pro as turn inducer together
with an adjacent lysine for functionalisation with reporter
groups might be useful as a general approach for the design of
other imaging probes. Potentially, this approach may stimulate
the design of other turn mimetic-based radiotracers, especially
those targeting G-protein coupled receptors, as many ligands
of peptide-activated GPCRs bind to their receptors in β-turn-
like conformations.66,67
Experimental section
General
All commercial reagents and solvents were used without
further purification unless otherwise specified. Melting points
were determined on a Galen III Boetius apparatus from Cam-
bridge Instruments. Nuclear magnetic resonance spectra were
recorded on a Varian Unity 400 MHz or an Agilent Techno-
logies 400 MR spectrometer. Spectra were processed by using
MestreNova (version 6.1.1-6384).68 NMR chemical shifts were
referenced to the residual solvent resonances relative to tetra-
methylsilane (TMS). Mass spectra (ESI) were obtained on a
Micromass Quattro LC or a Waters Xevo TQ-S mass spectro-
meter each driven by the Mass Lynx software. Elemental analy-
sis was performed on a LECO CHNS-932 apparatus.
Determination of resin loading was performed on a Thermo
Scientific Helios α UV/Vis spectrophotometer.
Chromatography
Thin-layer chromatography (TLC) was performed on Merck
silica gel F-254 aluminium plates with visualisation under UV
(254 nm) and/or staining with a 0.1% (m V−1) ninhydrin solu-
tion in ethanol. Preparative column chromatography was
carried out using Merck silica gel (mesh size 230–400 ASTM)
with solvent mixtures as specified for the particular com-
pounds. Preparative HPLC for the purification of peptides 3,
3a, 8–10 was performed on a Varian Prepstar system equipped
with UV detector (Prostar, Varian) and automatic fraction col-
lector Foxy 200. A Microsorb C18 60-8 column (Varian
Dynamax 250 × 21.4 mm) was used as the stationary phase
and a binary gradient system of 0.1% CF3COOH–water (solvent
A) and 0.1% CF3COOH–CH3CN (solvent B) at a flow rate of
10 mL min−1 served as the eluent. The conditions for the gra-
dient elution are as follows: 0–3 min 90% A, 3–35 min gradient
Fig. 10 Stability of cyclohexapeptide 3 against cleavage by trypsin as
determined by RP-HPLC. Compound 3 was incubated with bovine
trypsin at varying concentrations over a time of 30 min. To distinguish
the signals that originate from the enzyme, trypsin alone was analysed
under the same conditions.
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to 35% B, 35–40 min gradient to 100% B, 40–45 min 100% B,
45–50 min gradient back to 90% A.
Analytical HPLC for both analyses of peptidic products as
well as stability assays outlined below was performed on an
Agilent Technologies 1200 LC system consisting of gradient
pump G1311A combined with degasser G1322A, autosampler
G1329A, column heater G1316A and diode array detector
G1315D. The system was operated by the Agilent Chemstation
2008 software. A Nucleosil Standard C18 100-7 column
(Macherey-Nagel EC 250 × 4.6) was used as stationary phase
and a binary gradient system of 0.1% CF3COOH–water (solvent
A) and 0.1% CF3COOH–CH3CN (solvent B) at a flow rate of
1 mL min−1 served as the eluent. The stationary phase was
kept at 30 °C and the programme for elution was as follows:
0–3 min 90% A, 3–35 min gradient to 35% B, 35–40 min gradi-
ent to 100% B, 40–45 min 100% B, 45–50 min gradient back to
90% A.
Synthetic procedures
Fmoc-Lys-OAll × TFA (1). The synthesis was accomplished in
orientation to procedures published in ref. 29, 69 and 70 with
slight modifications. To a solution of Fmoc-Lys(Boc)-OH
(2.00 g, 4.3 mmol, 1 equiv.) in CH3CN (10 mL) was added allyl
bromide (9.3 mL, 108 mmol, 25 equiv.) and DIPEA (1.5 mL,
8.6 mmol, 2 equiv.). After stirring for 5 h at 40 °C the reaction
mixture was diluted with ethyl acetate (100 mL) and succes-
sively washed with 0.1 M HCl (3 × 50 mL), saturated NaHCO3
(3 × 50 mL) and saturated NaCl (3 × 50 mL). The organic phase
was dried over Na2SO4 and evaporated to yield intermediary
Fmoc-Lys(Boc)-OAll as a yellow oil. The crude material was dis-
solved in CH2Cl2–TFA (1 : 1 v/v, 50 mL) and the resulting
orange solution was stirred for 2 h at room temperature. The
volatile components were removed in the N2 stream followed
by repeated evaporations from diethyl ether (3 × 30 mL). The
obtained brownish oily residue was purified via column
chromatography (gradient from CH2Cl2–CH3OH 95 : 5 to
CH2Cl2–CH3OH 80 : 20) to aﬀord 1 (2.03 g, 91%) as an oﬀ-
white, adhesive solid. Rf 0.55 (CHCl3–CH3OH–CH3COOH
75 : 25 : 2); 1H-NMR (DMSO-d6) δ: 7.89 (d,
3J = 7.5 Hz, 2H, 2 ×
CH of Fmoc), 7.83 (broad s, 3H, NH3
+), 7.79 (d, 3J = 7.9 Hz, 1H,
NH), 7.71 (dd, 3J = 7.4 Hz, 4J = 3.5 Hz, 2H, H-1,8 of Fmoc), 7.42
(t, 3J = 7.4 Hz, 2H, 2 × CH of Fmoc), 7.33 (t, 3J = 7.4 Hz, 2H, 2 ×
CH of Fmoc), 5.95–5.82 (m, 1H, CHvCH2), 5.30 (dd,
3J = 17.2
Hz, 2J = 1.5 Hz, 1H, CHvCHH), 5.20 (dd, 3J = 10.5 Hz, 2J = 1.4
Hz, 1H, CHvCHH), 4.58 (d, 3J = 5.3 Hz, 2H, CH2O of Fmoc),
4.38–4.26 (m, 2H, CH2O of allyl), 4.23 (t,
3J = 6.8 Hz, 1H, H-9 of
Fmoc), 4.08–4.00 (m, 1H, CαH), 2.84–2.68 (m, 2H, CεH2),
1.78–1.46 (m, 4H, 2 × CH2), 1.45–1.26 (m, 2H, CH2);
13C-NMR
(DMSO-d6) δ: 172.00, 157.98 (q,
2JC,F = 31.2 Hz, CO of TFA),
156.19, 143.75, 140.75, 132.39, 127.65, 127.07, 125.22, 120.14,
117.72, 65.63, 64.76, 53.76 (Cα), 46.65 (C-9 of Fmoc), 38.52,
30.04, 26.44, 22.44; 19F-NMR (DMSO-d6) δ: −74.13 (s, CF3);
ESI-MS (ESI+) m/z: calc. for C24H29N2O4 [M + H]
+, 409.21,
found 409.6.
Boc-Hnl-OH (4). The synthesis was accomplished in orien-
tation to procedures published in ref. 35 and 71 with slight
modifications. To a suspension of Boc-Lys-OH (5.00 g,
20.3 mmol) in water (78.5 ml) was added 4 M NaOH (7.85 mL)
at 60 °C followed by small portions of sodium nitroprusside
(9.23 g, 31.0 mmol) as solid. After complete addition of
sodium nitroprusside, more of 4 M NaOH (7.85 mL) was
added resulting in a pH of 9 to 10. The resulting red-brown
suspension was stirred for 6 h at 60 °C, then cooled in an ice
bath and treated with 1 M HCl until pH ≈ 1 was reached
(78.5 mL). The resulting dark brown suspension was extracted
with ethyl acetate (3 × 80 mL), the combined organic layers
were dried over Na2SO4 and the solvent was removed in vacuo.
The crude product was obtained as yellow oil, which spon-
taneously crystallised upon trying to dissolve in ethyl acetate
again. The precipitate was filtered oﬀ to obtain 2 (1.93 g, 38%)
as a fluﬀy white powder. Rf 0.23 (ethyl acetate–CH3COOH
99 : 1); m.p. 110–113 °C (Lit.72 112–113 °C); 1H-NMR (DMSO-
d6) δ: 12.37 (s, 1H, COOH), 7.02 (d,
3J = 8.0 Hz, 1H, NH), 4.35
(broad s, 1H, OH), 3.87–3.78 (m, 1H, CαH), 3.39–3.33 (m, 2H,
CεH2), 1.69–1.47 (m, 2H, CH2), 1.45–1.22 (s, 13H, 3 × CH3 of
Boc, 2 × CH2);
13C-NMR (DMSO-d6) δ: 174.25, 155.57, 77.89
(quart. C of Boc), 60.48 (Cε), 53.48 (Cα), 32.04, 30.66, 28.21 (3 ×
CH3 of Boc), 22.25; ESI-MS (ESI+) m/z: calc. for C11H22NO5
[M + H]+, 248.15, found 248.4; Elemental analysis: calc. for
C11H21NO5, C, 53.43; H, 8.56; N, 5.66; found C, 53.65; H, 8.61;
N, 5.61.
Boc-Hnl-OAll (5). The synthesis was accomplished according
to the C-terminal allyl-protection of Fmoc-Ser-OH described in
ref. 73. To a solution of 4 (1.60 g, 6.5 mmol, 1 equiv.) in DMF
(40 mL) DIPEA (2.2 mL, 13 mmol, 2 equiv.) and allyl bromide
were added dropwise at 0 °C. The resulting light yellow solu-
tion was stirred over night at room temperature. The reaction
mixture was then diluted with ethyl acetate (110 mL), washed
with water (4 × 100 mL) and saturated NaCl (1 × 100 ml). The
organic phase was dried over Na2SO4 and evaporated to obtain
a yellow oil. The crude product was purified via column chrom-
atography (gradient from petroleum ether–ethyl acetate 3 : 1
over 3 : 2 to 1 : 1). The product-containing fractions were com-
bined and evaporated to aﬀord 5 (1.22 g, 65%) as a yellow oil.
Rf 0.16 (petroleum ether–ethyl acetate 3 : 2);
1H-NMR (CDCl3)
δ: 5.97–5.84 (m, 1H, CHvCH2), 5.33 (d,
3J = 17.2 Hz, 1H,
CHvCHH), 5.25 (d, 3J = 10.4 Hz, 1H, CHvCHH), 5.08–5.00
(m, 1H, NH), 4.68–4.57 (m, 2H, CH2O of allyl), 4.33–4.28 (m,
1H, CαH), 3.64 (t,
3J = 6.3 Hz, 2H, CεH2), 1.90–1.39 (m, 15H, 3 ×
CH3 of Boc, 3 × CH2);
13C-NMR (CDCl3) δ: 172.67 (CO), 155.59
(CONH), 131.78 (CH of allyl), 118.94 (CH2 of allyl), 80.08
(quart. C of Boc), 65.98, 62.63, 53.48 (Cα), 32.76, 32.24, 28.47
(3 CH3 of Boc), 21.70; ESI-MS (ESI+) m/z: calc. for C14H26NO5
[M + H]+, 288.18, found 288.3; Elemental analysis: calc. for
C14H25NO5, C, 58.52; H, 8.77; N, 4.87; found C, 58.01; H, 8.64;
N, 4.78.
H-Hnl(Tfa)-OAll × TFA (6). The synthesis was accomplished
according to the Boc-deprotection of Fmoc-Lys(Boc)-OH in ref.
29, 69 and 70. Compound 5 (1.17 g, 4.1 mmol) was dissolved
in CH2Cl2–TFA mixture (1 : 1 v/v, 50 mL) and the resulting solu-
tion was stirred for 2 h at room temperature. The volatile com-
ponents were removed in the N2 stream followed by repeated
Organic & Biomolecular Chemistry Paper
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evaporations from diethyl ether (3 × 20 mL). The obtained
residue was exposed to oil pump vacuum to remove remaining
TFA. 1.84 g (quantitative yield containing 12% of residual TFA)
of a brown oil were yielded. 1H-NMR (DMSO-d6) δ: 8.42 (s, 3H,
NH3
+), 5.99–5.87 (m, 1H, CHvCH2), 5.38 (dd,
3J = 17.3 Hz, 2J =
1.5 Hz, 1H, CHvCHH), 5.28 (dd, 3J = 10.5 Hz, 2J = 1.3 Hz, 1H,
CHvCHH), 4.70 (d, 3J = 5.0 Hz, 2H, CH2O of allyl), 4.38 (t,
3J =
6.3 Hz, 2H, CεH2), 4.16–4.07 (m, 1H, CαH), 1.91–1.64 (m, 4H, 3
× CH2), 1.56–1.31 (m, 2H, CH2);
19F-NMR (DMSO-d6) δ: −74.75
(s, CF3 of TFA), −74.79 (s, CF3 of Tfa); ESI-MS (ESI+) m/z: calc.
for C11H17F3NO4 [M + H]
+, 284.11, found 284.3.
Fmoc-Hnl-OAll (7). The synthesis was accomplished accord-
ing to the Fmoc-protection of Lys(Dnp) described in ref. 74.
Fmoc-OSu (1.72g, 5.1 mmol) was dissolved in DME (30 mL)
and a suspension of 6 (1.84g containing residual TFA,
4.1 mmol) in 0.62 M Na2CO3 (10 mL; 1.5 equiv. with respect to
6) was added slowly under ice cooling. The reaction mixture
was stirred for 2 h at 4 °C and afterwards over night at room
temperature. The suspension was filtered and the filtrate was
adjusted to pH ≈ 3 with 1 M HCl. DME was evaporated and
the residual aqueous solution was extracted with ethyl acetate
(3 × 20 mL). The combined organic phases were washed with
water (1 × 10 mL), saturated NaHCO3 (1 × 10 mL) and saturated
NaCl (1 × 10 mL), dried over Na2SO4 and evaporated in vacuo.
The obtained oily material was purified via column chromato-
graphy (gradient from petroleum ether–ethyl acetate 3 : 1 to
1 : 1). The product-containing fractions were combined to
yield 7 (0.97 g, 58%) as colourless oil that solidified in the
refrigerator. Rf 0.22 (petroleum ether–ethyl acetate 1 : 1);
m.p. 100–103 °C; 1H-NMR (CDCl3) δ: 7.77 (d,
3J = 7.6 Hz, 2H,
H-4,5 of Fmoc), 7.60 (d, 3J = 7.0 Hz, 2H, 2 × CH of Fmoc), 7.40
(t, 3J = 7.4 Hz, 2H, 2 × CH of Fmoc), 7.35–7.29 (m, 2H, 2 × CH
of Fmoc), 5.98–5.84 (m, 1H, CHvCH2), 5.40–5.23 (m, 2H,
CHvCHH, NH), 5.27 (dd, 3J = 10.4 Hz, 2J = 1.0 Hz, 1H,
CHvCHH), 4.65 (d, 3J = 5.5 Hz, 2H, CH2O of allyl) 4.45–4.35
(m, 3H, CH2O of Fmoc and CαH), 4.23 (t,
3J = 7.0 Hz, 1H, H-9
of Fmoc), 3.65 (t, 3J = 6.3 Hz, 2H, CεH2), 1.95–1.40 (m, 6H, 3 ×
CH2);
13C-NMR (CDCl3) δ: 172.34, 156.10, 143.96, 141.46,
131.64, 127.85, 127.20, 125.22, 120.13, 119.14, 67.16 (CH2O of
Fmoc), 66.16, 62.58, 53.95 (Cα), 47.32 (C-9 of Fmoc), 32.63,
32.19, 21.64; ESI-MS (ESI+) m/z: calc. for C24H28NO5 [M + H]
+,
410.20, found 410.2; Elemental analysis: calc. for C24H27NO5,
C, 70.49; H, 6.65; N, 3.42; found C, 69.89; H, 6.67; N, 3.43.
Procedures for loading of allyl esters 1 and 7 onto 2-ClTrtCl
resin
Loading of Fmoc-Lys-OAll × TFA (1) onto 2-ClTrtCl resin.
The synthesis was accomplished according to ref. 29. A solu-
tion of 1 (226.8 mg, 0.43 mmol, 0.5 equiv.) and DIPEA
(0.15 ml, 0.87 mmol, 1 equiv.) in THF (5 mL) was added to the
preswollen (5 mL THF, 1 h) 2-ClTrtCl resin (560.0 mg,
0.87 mmol, 1 equiv., 1.55 mmol g−1) in a PP filter vessel. The
PP filter vessel was sealed and agitated for 2 h at room tem-
perature. The resin was successively washed with DMF (4 mL,
4 × 1 min), CH2Cl2 (4 mL, 4 × 1 min), CH2Cl2–CH3OH–DIPEA
(17/1/2, 4 mL, 3 × 2 min) and finally with CH2Cl2 (4 mL, 4 ×
1 min) again. The resin was dried in vacuo over night.
Loading of Fmoc-Hnl-OAll (7) onto 2-ClTrtCl resin
High loading. The synthesis was accomplished according to
ref. 36. A solution of 7 (634.7 mg, 1.55 mmol, 1 equiv.) in
CH2Cl2–DMF (1 : 1, 6 mL) was added to the preswollen
(CH2Cl2, 6 mL, 30 min) 2-ClTrtCl resin (1.00 g, 1.55 mmol,
1 equiv.) in a PP filter vessel. Pyridine (0.5 mL, 6.2 mmol,
4 equiv.) was added subsequently and the mixture was sealed
and agitated for 65 h at room temperature. The resin was suc-
cessively washed with DMF (4 mL, 4 × 1 min), CH2Cl2 (4 mL,
4 × 1 min), CH2Cl2–CH3OH–DIPEA (17 : 1 : 2, 5 mL, 3 × 2 min)
and finally with CH2Cl2 (4 mL, 4 × 1 min). The resin was dried
in vacuo over night.
Low loading. A solution of 7 (270.3 mg, 0.66 mmol, 0.6
equiv.) in CH2Cl2–DMF (1 : 1, 5 mL) was added to the pre-
swollen (CH2Cl2, 6 mL, 30 min) 2-ClTrtCl resin (712 mg,
1.10 mmol, 1 equiv.) in a PP filter vessel. Pyridine (213 µL,
2.64 mmol, 2.4 equiv.) was added subsequently and the
mixture was sealed and agitated for 24 h at room temperature.
The resin was successively washed with DMF (4 mL, 4 ×
1 min), CH2Cl2 (4 mL, 4 × 1 min), CH2Cl2–CH3OH–DIPEA
(17 : 1 : 2, 5 mL, 3 × 2 min) and finally with CH2Cl2 (4 mL, 4 ×
1 min). The resin was dried in vacuo over night.
Determination of the loading yield
The determination was accomplished according to ref. 75 with
two aliquots of the resin. About 5 mg of the resin (exact value
has to be noted) containing the Fmoc-protected amino acid
allyl esters were placed into a PP reaction vessel and swollen in
DMF (2 mL) for 30 min. The suspension was filtered and the
resin was treated with 2% DBU in DMF (2 mL) and stirred for
another 30 min. The suspension was filtered into a graduated
10 mL flask and the resin was washed with CH3CN (3 × 1 mL).
Each filtrate was added to the flask and the solution was
diluted to 10 mL with CH3CN. 2 mL of this solution were
transferred to a graduated 25 ml flask and diluted with CH3CN
to 25 mL. A reference solution was prepared the same way but
without addition of the resin. The sample solutions were
measured against the reference at 294 nm in the UV/Vis
spectrometer. The loading yield was calculated by using the
following equation.
Loading ðmmol g1Þ294 nm ¼ ðE  14 214 μmolÞ=mresin
Finally the average value was calculated.
Procedures for the syntheses of the peptides 2, 3, 3a, 8–10 on
the 2-ClTrtCl resin
Synthesis of the linear peptide precursors. The linear penta-
and hexapeptides were assembled on the 2-ClTrtCl resin
loaded with the side-chain attached Fmoc/allyl-protected
amino acid derivatives by microwave-assisted solid phase
peptide synthesis using the CEM Liberty 12-channel peptide
synthesizer with integrated microwave reactor following a stan-
dard Fmoc protocol. The resin (0.1 mmol amino acid, 1 equiv.)
was swollen in DMF (5 mL) for 30 min outside the peptide
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synthesizer. After transfer to the reaction vessel, the resin was
swollen in CH2Cl2–DMF (1 : 1, 10 mL) for another 15 min.
Removal of the Fmoc groups (except for N-terminal serine) was
performed by using a solution of 20% piperidine in DMF with
0.1 M HOBt (1 × 7 mL at 35 W for 30 s and 1 × 7 mL at 44 W
for 180 s, both at 75 °C). After each treatment, the resin was
washed with DMF (5 + 28 mL). Coupling of each amino acid
was performed with two solutions: 0.45 M HBTU in DMF
(1 mL, 4.5 equiv.) and 2 M DIPEA in NMP (0.5 mL). The amino
acids were applied as 0.2 M solutions in DMF. 2.5 mL
(5 equiv.) of these solutions were taken for the coupling steps
(300 s at 21 W and 75 °C). The peptidyl resin containing the
protected linear precursor peptide was then washed with DMF
(21 mL) and outside the peptide synthesizer with ethanol
(4 × 5 mL) and CH2Cl2 (4 × 5 mL).
Removal of Allyl and Fmoc protecting groups. The deprotec-
tions were accomplished according to ref. 31. The peptidyl
resin (0.1 mmol peptide, 1 equiv.) was swollen in CH2Cl2
(6 mL) for 30 min and then suspended in CH2Cl2–NMM–
CH3COOH (8 : 2 : 1, 6 mL). After 2 min of degassing with Ar,
Pd(PPh3)4 (57.8 mg, 0.05 mmol, kept under Ar atmosphere) was
added to the mixture and the newly formed yellow suspension
was degassed for another 2 min with Ar. The PP filter vessel
was sealed and agitated for 4 h. The suspension was filtered
and the peptidyl resin was successively washed with CH2Cl2
(5 mL, 4 × 1 min), DMF (5 mL, 4 × 1 min), 0.5% w/v sodium
diethyldithiocarbamate in DMF (5 mL, 6 × 1 min) and finally
with DMF (5 mL, 5 × 1 min) again. The removal of the Fmoc
group was performed by treatment of the peptidyl resin with
20% piperidine in DMF (6 mL, 2 × 8 min). Then the peptidyl
resin was washed with DMF (6 mL, 3 × 1 min), 5% DIPEA in
DMF (6 mL, 3 × 1 min), DMF (6 mL, 1 × 1 min) and CH2Cl2
(6 mL, 5 × 1 min). The peptidyl resin was dried in vacuo over
night.
Cyclisation. The cyclisation was accomplished according to
ref. 29. The peptidyl resin (0.1 mmol peptide, 1 equiv.) was
swollen in DMF (4 mL) for 30 min. DIPEA (34 µL, 0.05 mmol, 2
equiv.) and HATU (57.0 mg, 0.15 mmol, 1.5 equiv.) were added
and the newly formed orange suspension was agitated for 4 h
at room temperature. The peptidyl resin was washed with DMF
(5 mL, 5 × 1 min) and CH2Cl2 (5 mL, 4 × 1 min) and dried in
vacuo over night. The cyclisation was repeated until three
times with respect to the cyclisation yield.
Removal of the Dde protecting groups. The deprotection
was accomplished according to the procedure published in ref.
76. The peptidyl resin (0.1 mmol peptide) was swollen in DMF
(4 mL) for 30 min before treated with 2% N2H4 in DMF (5 mL,
5–12 × 5 min). The filtrates were collected and the extinctions
measured against the N2H4 solution at λ = 300 nm. Constant
extinction values close to zero indicate complete removal of
the Dde group. The peptidyl resin was washed with DMF
(4 mL, 4 × 1 min) and CH2Cl2 (4 mL, 4 × 1 min) and dried
in vacuo over night.
Fluorobenzoylation. The peptidyl resin (0.1 mmol peptide,
1 equiv.) was swollen in CH2Cl2 (5 mL, 30 min) and TEA
(34.8 µL, 0.25 mmol, 2.5 equiv.) and 4-fluorobenzoyl chloride
(29.5 µL, 0.25 mmol, 2.5 equiv.) were added to the suspension.
The mixture was agitated for 2 h at room temperature. The
peptidyl resin was washed with CH2Cl2 (5 mL, 4 × 1 min) and
dried in vacuo over night.
Procedures for cleavage of the peptides from the 2-ClTrtCl
resin and/or the protecting groups
Simultaneous cleavage of resin bond and t-butyl protecting
groups. The cleavage was accomplished according to ref. 29.
The synthesis steps after assembly of the linear protected pre-
cursors were monitored by subjecting small portions to clea-
vage from resin after each step and analysis by ESI-MS.
Therefore, the volumes of the mixtures used for cleavage and
washing are diﬀerent compared to the complete release of the
peptide from the resin.
The dry peptidyl resin was suspended in 1 or 3 mL of a
solution of TFA–TES–H2O (95 : 2.5 : 2.5) for 1 or 3 h for small-
scale analytical or complete cleavage, respectively. After filter-
ing, the resin was washed with TFA (2 × 1 or 5 mL for analytical
and complete cleavage, respectively) and the combined fil-
trates were evaporated in a N2 stream. Ice-cold diethyl ether
(10 mL) was added to the oily residue and the mixture was
cooled on ice for 30 min. After this, the newly formed white,
voluminous precipitate was filtered oﬀ and dried in vacuo.
Release of side-chain protected cyclohexapeptide 8 from
resin. The dry peptidyl resin (0.11 mmol peptide) was sus-
pended in 3 mL of a solution of TFA–TES–CH2Cl2 (1 : 5 : 94) for
30 min. After filtering and washing of the resin with CH2Cl2
(1 × 4 mL), NaHCO3 (52 mg) was added to the combined filtrates
and the suspension was stirred for 10 min. After renewed fil-
tration, the filtrate was evaporated in a N2 stream. The oily
residue was dissolved in CH3CN–H2O (1 mL, 1 : 1) and stirred
over night. Finally, the solution was evaporated in vacuo and
lyophilised.
Cleavage of t-butyl protecting groups from tri-tBu-9. The dry
fully protected peptidyl aldehyde 9 (43 µmol) was dissolved in
TFA–CH2Cl2 (5 mL, 9 : 1) and stirred for 1 h. The solution was
evaporated in a N2 stream. Ice-cold diethyl ether (10 mL) was
added to the oily residue and the mixture was kept on ice for
30 min. After this, the newly formed white, voluminous pre-
cipitate was filtered oﬀ and dried in vacuo.
Oxidation with Dess-Martin periodinane. To a solution of
the fully protected peptidyl alcohol 8 (43 µmol) in CH2Cl2
(5 mL) was added DMP suspended in CH2Cl2 (1.5 mL). The
resulting turbid solution was stirred at room temperature and
the oxidation was followed by ESI-MS analysis of a small solu-
tion sample. After 3 h, no remaining alcohol was detectable
and 1.3 M NaOH (20 mL) and CH2Cl2 (10 mL) were added and
the solution was stirred for 15 min. The organic layer was sepa-
rated and washed successively with 1.3 M NaOH (2 × 10 mL)
and brine (1 × 10 mL). After that, the organic layer was dried
over NaSO4 and evaporated in vacuo.
Analytical data for the peptides
Cyclo(Ser-Lys(FBz)-Asp-Glu-Lys) × TFA (2). Initial loading of
0.26 mmol g−1; 36.1 mg crude product resulted in 8.1 mg
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(22%) purified peptide; RP-HPLC analysis: tR = 15.8 min;
ESI-MS (ESI+) m/z: calc. for C31H45FN7O11, [M + H]
+, 710.32,
found 711.2.
Cyclo(Ser-D-Pro-Lys(FBz)-Asp-Glu-Lys) × TFA (3). Initial
loading of 0.23 mmol g−1; 34.4 mg crude product resulted in
27.5 mg (80%) purified peptide; RP-HPLC analysis: tR =
14.2 min; 1H-NMR (DMSO-d6) δ: Ser: 6.83 (d,
3J = 6.0 Hz, NH),
4.57–4.49 (m, CαH), 3.71–3.62 (m, CβHH), 3.35 (t,
3J = 2J = 9.4
Hz, CβHH) D-Pro: 4.31–4.26 (m, CαH), 3.79–3.71 (m, CδHH),
3.62–3.53 (m, CδHH), 2.12–1.73 (m, CβH2, CγH2) Lys (FBz): 8.51
(d, 3J = 8.4 Hz, CαNH), 8.46 (t,
3J = 5.6 Hz, CεNH), 7.90 (dd,
3JH,
H = 8.8 Hz,
4JH,F = 5.5 Hz, H-2,6 of FBz), 7.28 (t,
3JH,H =
3JH,F =
8.9 Hz, H-3,5 of FBz), 4.08–4.00 (m, CαH), 3.29–3.16 (m, CεH2),
2.12–1.73 (m, CβH2), 1.67–1.41 (m, CδH2), 1.41–1.15 (m, CγH2)
Asp: 7.98 (d, 3J = 9.3 Hz, NH), 4.80–4.71 (m, CαH), 3.11 (d,
2J =
14.0 Hz, CβHH), 2.86 (dd,
2J = 17.2 Hz, 3J = 9.9 Hz, CβHH) Glu:
8.21 (d, 3J = 3.0 Hz, NH), 3.71–3.62 (m, CαH), 2.41–2.25 (m,
CγH2), 2.12–1.73 (m, CβH2) Lys: 7.87 (d,
3J = 8.6 Hz, NH), 7.65
(broad s, NH3
+), 4.19–4.10 (m, CαH), 2.80–2.68 (m, CεH2),
2.12–1.73 (m, CβH2), 1.67–1.41 (m, CδH2), 1.41–1.15 (m, CγH2);
13C-NMR (DMSO-d6) δ: 172.43, 171.08, 170.60, 170.56, 170.50,
170.20, 169.45, 167.35, 163.78, 162.50 (d, 1JC,F = 247.9 Hz, C-4
of FBz), 156.90 (d, 2JC,F = 34.6 Hz, CO of TFA), 130.22 (d,
4JC,F =
2.9 Hz, C-1 of FBz), 128.83 (d, 3JC,F = 8.9 Hz, C-2.6 of FBz),
114.34 (d, 2JC,F = 21.7 Hz, C-3,5 of FBz), 73.99, 61.63, 59.75,
55.87, 52.80, 52.71, 52.33, 48.35, 47.32, 38.71, 38.66, 36.91,
30.81, 30.23, 28.83, 28.79, 26.40, 25.86, 24.94, 23.22, 22.63;
19F-NMR (DMSO-d6) δ: −75.02 (s, CF3 of TFA), −110.30–
−110.40 (m, FBz); ESI-MS (ESI+) m/z: calc. for C36H52FN8O12,
[M + H]+, 807.37, found 808.1.
1H-NMR (water) δ: Ser: 7.46 (d, 3J = 6.5 Hz, NH), 3.87–3.76
(m, CβH2), CαH lies under the water signal D-Pro: 4.37–4.32 (m,
CαH), 3.76–3.65 (m, CδH2), 2.21–1.55 (m, CβH2, CγH2) Lys
(FBz): 8.72 (d, 3J = 7.4 Hz, CαNH), 8.46 (t,
3J = 5.8 Hz, CεNH),
7.79 (dd, 3JH,H = 8.7 Hz,
4JH,F = 5.4 Hz, H-2,6 FBz), 7.24 (t,
3JH,H
= 3JH,F = 8.8 Hz, H-3,5 FBz), 4.32–4.21 (m, CαH), 3.45–3.34 (m,
CεH2), 2.21–1.55 (m, CβH2, CδH2), 1.54–1.31 (m, CγH2) Asp:
8.24 (d, 3J = 9.1 Hz, NH), 3.07–2.89 (m, CβH2), CαH lies under
the water signal Glu: 8.41 (d, 3J = 4.0 Hz, NH), 4.04–3.97 (m,
CαH), 2.58–2.37 (m, CγH2), 2.21–1.55 (m, CβH2) Lys: 8.31 (d,
3J
= 7.5 Hz, NH), 7.53 (broad s, NH3
+), 4.32–4.21 (m, CαH),
3.07–2.89 (m, 2H, CεH2), 2.21–1.55 (m, CβH2 and CδH2),
1.54–1.31 (m, CγH2).
Cyclo(Ser-D-Pro-Lys-Asp-Glu-Lys) × 2TFA (3a). Initial loading
of 0.23 mmol g−1, 19.9 mg crude product resulted in 8.6 mg
(43%) purified peptide; 1H-NMR (water) δ: Ser: 7.45 (d, 3J = 6.7
Hz, NH), 3.86–3.81 (m, CβH2), CαH lies under the water signal
D-Pro: 4.43–4.38 (m, CαH), 3.79–3.69 (m, CδH2), 2.33–2.21 (m,
CβHH), 2.21–2.07 (m, CγHH), 2.07–1.89 (m, CβHH, CγHH) Lys:
8.77 (d, 3J = 7.5 Hz, CαNH), 7.53 (broad s, NH3
+), 4.35–4.22 (m,
CαH), 3.05–2.94 (m, CεH2), 2.07–1.89 (m, CβHH), 1.78–1.60 (m,
CβHH, CδH2), 1.53–1.32 (m, CγH2) Asp: 8.27 (d,
3J = 9.1 Hz,
NH), 4.98–4.94 (m, CαH), 3.11–3.06 (m, CβH2) Glu: 8.44 (d,
3J =
4.0 Hz, NH), 4.04–3.97 (m, CαH), 2.61–2.41 (m, CγH2),
2.21–2.07 (m, CβH2) Lys: 8.31 (d,
3J = 7.4 Hz, NH), 7.53 (broad
s, NH3
+), 4.35–4.22 (m, CαH), 3.05–2.94 (m, CεH2), 2.07–1.89
(m, CβHH), 1.89–1.79 (m, CβHH), 1.78–1.60 (m, CδH2),
1.53–1.32 (m, CγH2); ESI-MS (ESI+) m/z: calc. for
C29H49FN8O11, [M + H]
+, 685.35, found 685.2.
Cyclo(Ser-D-Pro-Lys(FBz)-Asp-Glu-Hnl) (8). Initial loading of
0.86 mmol g−1; 114.4 mg crude product resulted in 34.3 mg
(30%) purified peptide; RP-HPLC analysis: tR = 14.9 min;
1H-NMR (DMSO-d6) δ: Ser: 6.79 (d,
3J = 6,1 Hz, NH), 4.57–4.48
(m, CαH), 3.71–3.62 (m, CβHH), 3.39–3.28 (m, CβHH) D-Pro:
4.31–4.25 (m, CαH), 3.80–3.71 (m, CδHH), 3.62–3.53 (m, CδHH),
2.12–1.71 (m, CβH2, CγH2) Lys (FBz): 8.52 (d,
3J = 8.2 Hz,
CαNH), 8.46 (t,
3J = 5.4 Hz, CεNH), 7.90 (dd,
3JH,H = 8.7 Hz,
4JH,F
= 5.6 Hz, H–2,6 FBz), 7.28 (t, 3JH,H =
3JH,F = 8.8 Hz, H–3,5 FBz),
4.07–4.00 (m, CαH), 3.27–3.18 (m, CεH2), 2.12–1.71 (m, CβHH),
1.63–1.43 (m, CδH2, CβHH), 1.43–1.11 (m, CγH2) Asp: 7.97 (d,
3J
= 9.4 Hz, NH), 4.81–4.71 (m, CαH), 3.12 (d,
2J = 17.1 Hz, 3J = 2.7
Hz, CβHH), 2.88 (dd,
2J = 17.3 Hz, 3J = 9.8 Hz, CβHH) Glu: 8.17
(d, 3J = 2.6 Hz, NH), 3.71–3.62 (m, CαH), 2.38–2.27 (m, CγH2),
2.12–1.71 (m, CβH2) Hnl: 7.82 (d,
3J = 8.4 Hz, NH), 4.17–4.08
(m, CαH), 3.39–3.28 (m, CεH2), 2.12–1.71 (m, CβHH), 1.63–1.43
(m, CβHH), 1.43–1.11 (m, CγH2, CδH2);
13C-NMR (DMSO-d6) δ:
173.74, 172.49, 171.96, 171.91, 171.89, 171.77, 170.65, 168.72,
165.07, 163.76 (d, 1JC,F = 248.2 Hz, C-4 FBz), 131.15 (d,
4JC,F =
2.9 Hz, C-1 FBz), 129.76 (d, 3JC,F = 9.0 Hz, C-2,6 FBz), 115.12 (d,
2JC,F = 21.7 Hz, C-3,5 FBz), 61.96, 60.55, 60.00, 56.08, 52.95,
52.85, 48.46, 47.45, 38.74, 36.91, 31.86, 31.29, 30.19, 30.10,
28.74, 25.80, 24.84, 23.09, 22.24. Two signals are missing (Cα
and methylene group); 19F-NMR (DMSO-d6) δ: −110.33 (tt, 3JF,H
= 8.9 Hz, 4JF,H = 5.6 Hz, FBz); ESI-MS (ESI+) m/z: calc. for
C36H51FN7O13, [M + H]
+, 808.35, found 809.0.
Cyclo(Ser-D-Pro-Lys(FBz)-Asp-Glu-Aly) (9). Initial loading of
0.46 mmol g−1; 22.6 mg crude product resulted in 5.7 mg
(25%) purified peptide; RP-HPLC analysis: tR = 15.1 min;
1H-NMR (DMSO-d6) δ: Ser: 6.83 (d,
3J = 6.2 Hz, NH), 5.09–5.02
(m, OH), 4.57–4.48 (m, CαH), 3.71–3.62 (m, CβHH) (second
CβH of Serine lies under water signal) D-Pro: 4.32–4.25 (m,
CαH), 3.80–3.71 (m, CδHH), 3.62–3.53 (m, CδHH), 2.11–1.70 (m,
CβH2 und CγH2) Lys (FBz): 8.51 (d,
3J = 8.2 Hz, CαNH), 8.46 (t,
3J = 5.4 Hz, CεNH), 7.90 (dd,
3JH,H = 8.8 Hz,
4JH,F = 5.6 Hz,
H-2,6 FBz), 7.28 (t, 3JH,H =
3JH,F = 8.8 Hz, H-3,5 FBz), 4.08–3.99
(m, CαH), 3.27–3.19 (m, CεH2), 2.11–1.70 (m, CβH2), 1.64–1.20
(m, CγH2, CδH2) Asp: 7.97 (d,
3J = 9.3 Hz, NH), 4.80–4.71 (m,
CαH), 3.10 (d,
2J = 17.1 Hz, 3J = 2.5 Hz, CβHH), 2.87 (dd,
2J =
17.3 Hz, 3J = 9.7 Hz, CβHH) Glu: 8.19 (d,
3J = 2.5 Hz, NH),
3.71–3.62 (m, CαH), 2.38–2.28 (m, CγH2), 2.11–1.70 (m, CβH2)
Aly: 9.64 (s, CHO), 7.86 (d, 3J = 8.8 Hz, NH), 4.16–4.09 (m,
CαH), 2.45–2.38 (m, CδH2), 2.11–1.70 (m, CβH2), 1.64–1.20 (m,
CγH2);
13C-NMR (DMSO-d6) δ: 203.10, 173.69, 172.41, 171.95,
171.87, 171.82, 171.41, 170.71, 168.66, 165.02, 163.73 (d, 1JC,F =
247.7 Hz, C-4 FBz), 131.14 (d, 4JC,F = 2.7 Hz, C-1 FBz), 129.73
(d, 3JC,F = 9.0 Hz, C-2,6 FBz), 115.09 (d,
2JC,F = 21.6 Hz, C-3,5
FBz), 61.83, 59.96, 55.98, 52.96, 52.84, 52.74, 48.45, 47.39,
42.33, 38.73, 36.89, 30.78, 30.17, 30.09, 28.72, 25.73, 24.81,
23.07, 18.38 (one signal of a methylene group is missing);
19F-NMR (DMSO-d6) δ: −109.95 (tt, 3JF,H = 8.8 Hz, 4JF,H = 5.2
Hz, FBz); ESI-MS (ESI+) m/z: calc. for C36H49FN7O13, [M + H]
+,
806.34, found 806.5.
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Ac-Lys(FBz)-Asp-Glu-Lys-Ser-D-Pro-NH2 × TFA (10). Initial
loading of 0.60 mmol g−1 (Rink-Amid resin); 140.5 mg crude
product resulted in 103.1 mg (74%) purified peptide. RP-HPLC
analysis: tR = 12.9 min; mixture of D-Pro s-trans/s-cis isomers
(ratio 7 : 3), NMR signals are only listed for the major isomer:
1H-NMR (DMSO-d6) δ: Lys (FBz): 8.46 (t,
3J = 5.5 Hz, CεNH),
8.09 (d, 3J = 6.9 Hz, CαNH), 7.90 (dd,
3JH,H = 8.8 Hz,
4JH,F = 5.6
Hz, H-2,6 FBz), 7.28 (t, 3JH,H =
3JH,F = 8.8 Hz, H-3,5 FBz),
4.16–4.07 (m, CαH), 3.27–3.18 (m, CεH2), 1.94–1.80 (m, CH3),
1.66–1.56 (m, CβHH), 1.56–1.42 (m, CβHH, CδH2), 1.41–1.20
(m, CγH2) Asp: 8.29 (d,
3J = 7.7 Hz, NH), 4.56–4.46 (m, CαH),
2.80–2.69 (m, CβHH), 2.59–2.49 (m, CβHH) Glu: 7.65 (d,
3J = 8.1
Hz, NH), 4.34–4.16 (m, CαH), 2.34–2.12 (m, CγH2), 1.94–1.80
(m, CβHH), 1.80–1.67 (m, CβHH) Lys: 7.85 (d,
3J = 7.8 Hz, NH),
7.72–7.57 (broad s, NH3
+), 4.34–4.16 (m, CαH), 2.80–2.69 (m,
CεH2), 1.66–1.56 (m, CβHH), 1.56–1.42 (m, CβHH, CδH2),
1.41–1.20 (m, CγH2) Ser: 8.20 (d,
3J = 6.8 Hz, NH), 4.56–4.46
(m, CαH), 3.67–3.55 (m, CβHH), 3.53–3.43 (m, CβHH) D-Pro:
7.05 (s, NHH), 6.91 (s, NHH), 4.34–4.16 (m, CαH), 3.75–3.67 (m,
CδHH), 3.67–3.55 (m, CδHH), 2.08–1.95 (m, CβHH), 1.94–1.80
(m, CβHH, CγH2);
13C-NMR (DMSO-d6) δ: 174.06, 173.59,
172.16, 171.97, 171.55, 170.64, 170.41, 170.02, 169.11, 165.06,
163.74 (d, 1JC,F = 248.1 Hz, C-4 FBz), 158.08 (q,
2JC,F = 34.7 Hz,
CO TFA), 131.10 (d, 4JC,F = 2.9 Hz, C-1 FBz), 129.73 (d,
3JC,F =
9.0 Hz, C-2,6 FBz), 115.11 (d, 2JC,F = 21.7 Hz, C-3,5 FBz), 61.06,
59.63, 53.15, 53.03, 51.85, 51.78, 49.55, 46.79, 38.75, 35.58,
31.31, 29.99, 29.28, 28.84, 27.22, 26.56, 23.99, 22.86, 22.40,
21.84, signal for one methylene group is missing; 19F-NMR
(DMSO-d6) δ: −74.93 (s, CF3 TFA-Anion), −110.28 (tt, 3JFH = 8.8
Hz, 4JFH = 5.6 Hz, FBz); ESI-MS (ESI+) m/z: calc. for
C38H57FN9O13, [M + H]
+, 866.41, found 866.1.
NMR spectroscopy
The compounds 3, 8, 9 and 10 were dissolved in 600 µL of
DMSO-d6. Additionally, compounds 3 and 3a were dissolved in
600 µL of H2O. In this case, an capillary insert containing D2O
was placed into the sample tube to allow shiming. The H2O
peak was suppressed by water presaturation. The 1D and 2D
1H NMR experiments (COSY, TOCSY (mixing time/spin-lock
time 120 ms), and ROESY (mixing time 300 ms)) were acquired
on a Varian 400 MHz or an Agilent Technologies 400 MR
spectrometer at 298 K. VT-NMR experiments were performed
to monitor amide exchange rates at varying temperatures up to
318 K in 5 K intervals. 3JNHCHα coupling constants were
measured from 1H NMR spectra and ROE intensities were col-
lected manually.
ECD spectroscopy
Stock solutions of the peptides 3, 8, 9, and 10 were prepared in
a concentration 0.5 mg mL−1 in 10 mM sodium phosphate pH
7.4. The ECD spectra were measured in a quartz cuvette with
an optical path length of 1 mm (Starna, USA) using a J-810
spectropolarimeter (Jasco, Japan). The conditions of the
measurements were as follows: a spectral region of 200 (180)–
400 nm, a scanning speed of 20 nm min−1, a response time of
8 s, a resolution of 1 nm, a bandwidth of 1 nm and a sensi-
tivity of 100 mdeg. The final spectrum was obtained as an
average of 5 accumulations. The spectra were corrected for a
baseline by subtracting the spectra of the corresponding poly-
peptide-free solution. The ECD measurements were conducted
at room temperature.
IR and VCD spectroscopy
Solutions of peptides 3, 8, 9, and 10 were prepared in DMSO to
a concentration of 20 mg mL−1 in a total volume of 100 µL
each. The VCD and infrared absorption spectra in the
1800–1400 cm−1 region were measured on a FTIR IFS 66/S
spectrometer equipped with a PMA 37 VCD/IRRAS module
(Bruker, Germany). The samples were placed in a demountable
cell (A145, Bruker, Germany) composed of CaF2 windows sepa-
rated by a 23 µm Teflon spacer. All of the VCD spectra were
recorded at a spectral resolution of 8 cm−1 and are the average
of the 15 blocks of 3686 scans (20 minutes). The OPUS 6.5 soft-
ware (Bruker, Germany) was used for the VCD spectra calcu-
lations. The VCD spectra were corrected for a baseline, which
was obtained as the VCD spectrum of the polypeptide-free
solution measured under the same experimental conditions.
Stability studies for trypsin-mediated degradation
A solution of trypsin from bovine pancreas (Serva 37290, lyo-
philised powder, 4 U mg−1) was freshly prepared in 0.3 M Tris-
HCl pH 7.5 at a concentration of 1 mM and kept on ice. Stock
solutions of 3 and 10 (2 mM each) were prepared in 0.3 M Tris-
HCl pH 7.5. The peptide stock solutions were diluted with the
trypsin solution and 0.3 M Tris-HCl to reach a final peptide
concentration of 500 µM and enzyme concentrations of 0.1,
1.0, and 500 µM in a total volume of 100 µL. If necessary, the
enzyme stock solution was prediluted with 0.3 M Tris-HCl pH
7.5. The reaction mixtures were incubated at 37 °C for 30 min.
After this, an aliquot of 50 µL was withdrawn and added to 5 µL
of 6 M HCl, vortexed and centrifuged at 1000g for 30 s. 40 µL of
the supernatant was analysed by RP-HPLC as specified above.
Structure calculations
Distance restraints used in calculating a solution structure for
3, 8, and 9 in DMSO-d6 were derived from ROESY spectra. ROE
cross-peak volumes were classified manually as strong (upper
distance constraint ≤2.7 Å), medium (≤3.5 Å), weak (≤5.0 Å)
and very weak (≤6.0 Å). Standard pseudoatom distance correc-
tions were applied for non-stereospecifically assigned
protons.77 Conformational averaging was tackled by classifying
the intensities conservatively. Only upper distance limits were
included in the calculations to allow the largest possible
number of conformers to fit the experimental data. 3JNHCHα-
coupling constants measured from 1H NMR were used to
apply backbone dihedral angle restraints as follows: ϕ was
restrained to −120 ± 30° for 3JNHCHα ≥ 8 Hz and to −65 ± 30°
for 3JNHCHα ≤ 6 Hz. Starting structures with randomised ϕ and
ψ angles and extended side chains were generated using an ab
initio simulated annealing protocol.48 The calculations were
performed using the standard force field parameter set and
topology file included in Xplor-NIH 2.34 package47,78 within
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house modifications to generate the backbone connection
between the N-terminus of residue 1 and the C-terminus of
residue 6 as well as the unnatural amino acids Lys(FBz), Hnl,
and Aly. The final energy minimisation included 2000 steps of
the conjugate gradient Powell algorithm and energy mini-
mised using CHARMm force field.49 Final structures were visu-
alised with PyMOL4 and had no distance (>0.2 Å) or angle
(>2.4°) violations.
Molecular dynamics (MD) simulations
MD simulations of cyclohexapeptides 3 and 9 were carried out
using the ﬀ99SB force field59 and standard protocols as
implemented in the AMBER12 package (see below).60 Each
system was solvated in a truncated octahedral box of DMSO or
TIP3P water molecules and neutralised with Na+ counterions.
In the case of DMSO, the solvent dielectric constant was set to
47. Molecular dynamic simulations were preceded by two
energy-minimisation steps: (i) only the solvent and ions were
relaxed and position restraints were applied to the cyclohexa-
peptide (500 kcal mol−1 Å−2) using 1000 steps of steepest des-
cendent minimisation followed by 500 of conjugate gradient
minimisation; (ii) the entire system was minimised without
restraints by applying 3000 steps of steepest descendent and
3000 of conjugate gradient equilibration. Then the system was
heated up from 200 K to 300 K in 20 ps with weak position
restraints (10 kcal mol−1 Å−2) in the canonical ensemble
(NVT). Langevin temperature coupling with a collision fre-
quency γ = 1 ps−1 was used at this step. The system was equili-
brated without restraints for 15 ns in the isothermal-isobaric
ensemble (NPT) using the Langevin thermostat and Berendsen
barostat under periodic boundary conditions. For simulations
performed in DMSO, compressibility was set to 52.5 × 10−6
bar−1. A total of 100 ns unrestrained MD productions were
carried out at 300 K in the canonical (NVT) or in the isother-
mal-isobaric (NPT) ensembles. Berendsen thermostat was used
during NVT MD production. The SHAKE algorithm was used
to constrain all bonds involving hydrogen atoms. A time step
of 2 fs per step was used during the SHAKE algorithm. A cutoﬀ
of 8 Å was applied to treat the nonbonded interactions, and
the Particle Mesh Ewald (PME) method was used to treat long-
range electrostatic interactions. MD trajectories were recorded
every 2 ps. Lys(FBz) and Aly were parametrised according to the
ﬀ99SB force field, and missed parameters were taken from the
General Amber Force Field (GAFF).79 RESP charges were derived
at the HF/6-31G* calculation level using Gaussian 09 version
C.01.80–82 Trajectories were visualised with VMD.83 They were
evaluated in terms of RMSD, distances, dihedral angles, and
intramolecular H-bonds using the PTRAJ and CPPTRAJ modules
implemented in AMBER. Data analysis and graphical represen-
tation were carried out with the R-package.84
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